Spherical protein particles and methods for making and using...

Details Spherical protein particles and methods for making and using... Spherical protein particles and methods for making and using...

2011-08-16

2011-08-16

Lukton, David (Department: 1654)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C530S387100, C530S418000, C977S904000

Reexamination Certificate

active

07998477

ABSTRACT:
This invention relates to SPPs, spherical nanocrystalline composite particles or crystalline SPPs of biologically active proteins or compositions, including formulations, comprising such SPPs, spherical nanocrystalline composite particles or crystalline SPPs.More particularly, methods are provided for the production of SPPs, spherical nanocrystalline composite particles or crystalline SPPs of high concentrations of biologically active proteins, and for the preparation of stabilized SPPs, spherical nanocrystalline composite particles or crystalline SPPs for use alone, or in dry or slurry compositions. This invention also relates to methods for stabilization, storage and delivery of biologically active proteins using SPPs, spherical nanocrystalline composite particles or crystalline SPPs.The present invention further relates to methods using SPPs, spherical nanocrystalline composite particles or crystalline SPPs, or compositions or formulations comprising such SPPs, spherical nanocrystalline composite particles or crystalline SPPs, for biomedical applications, including biological delivery to humans and animals.

REFERENCES:
patent: 4334024 (1982-06-01), Johal
patent: 4959351 (1990-09-01), Grau
patent: 5510118 (1996-04-01), Bosch et al.
patent: 5751453 (1998-05-01), Baur
patent: 5780599 (1998-07-01), Junker et al.
patent: 5849296 (1998-12-01), Navia et al.
patent: 5904935 (1999-05-01), Eckenhoff et al.
patent: 5972331 (1999-10-01), Reichert et al.
patent: 6011001 (2000-01-01), Navia et al.
patent: 6042824 (2000-03-01), Khalaf
patent: 6063910 (2000-05-01), Debenedetti et al.
patent: 6140475 (2000-10-01), Margolin et al.
patent: 6143211 (2000-11-01), Mathiowitz et al.
patent: 6310038 (2001-10-01), Havelund
patent: 6458387 (2002-10-01), Scott et al.
patent: 6555110 (2003-04-01), D'Souza
patent: 6562952 (2003-05-01), Rajewski et al.
patent: 6630121 (2003-10-01), Sievers et al.
patent: 6652837 (2003-11-01), Edwards et al.
patent: 6727278 (2004-04-01), Averback
patent: 6756062 (2004-06-01), Johnston et al.
patent: 6794357 (2004-09-01), Edman et al.
patent: 6821429 (2004-11-01), Perrut
patent: 6835396 (2004-12-01), Brynjelsen et al.
patent: 6860907 (2005-03-01), Hanna et al.
patent: 6942868 (2005-09-01), Edwards et al.
patent: 6956021 (2005-10-01), Edwards et al.
patent: 2002/0136719 (2002-09-01), Shenoy et al.
patent: 2004/0219224 (2004-11-01), Yakovlevsky et al.
patent: 0166 233 (1986-01-01), None
patent: WO 9109943 (1991-07-01), None
patent: WO 9640049 (1996-12-01), None
patent: WO 9708300 (1997-03-01), None
patent: WO 9744445 (1997-11-01), None
patent: WO 9846732 (1998-10-01), None
patent: WO 9955310 (1999-11-01), None
patent: WO 0052150 (2000-08-01), None
patent: WO 0077281 (2000-12-01), None
Rembaum, Alan (Chemtech 8(3), 182-90, 1978).
Truong, Vu L. (Drug Delivery 2(3/4), 166-74, 1995).
Rembaum, A. (Science 208(4442), 364-8, 1980).
Rembaum, Alan (Pure and Applied Chemistry 52(5), 1275-78, 1980).
Holubar, K. (International Archives of Allergy and Applied Immunology 44(4), 489-499, 1973).
Harris L. J. (Proteins 23(2), 285-289, 1995).
Gross M., (Nature 373(6510), 105-106, 1995).
Kovari L. C. (Structure [London, England : 1993] 3(12), 1291-1293, 1995).
Edmundson A. B. (Immunotechnology : an international journal of immunological engineering 3(4), 309-317, 1998).
Patenaude S. I. (Acta crystallographica. Section D, Biological crystallography, D54, 1456-59, 1998).
English Abstract of Matsuura, Crystallization of Proteins, vol. 12, No. 1-2, 108, 1985.
Abstract of Blanco, Eur J Pharm Biopharm 45(3) 285-94, 1998.
Abstract of Kuttner, Mol Immunol 35(3) 189-94, 1998.
Babay, D., et al., “Design and release kinetic pattern evaluation of indomethacin microspheres intended for oral administration,”Biomaterials9:482-488 (1988).
Baselga, J., et al., “Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2
eu overexpressing human breast cancer xenografts,”Cancer Res. 58:2825-2831 (1998); Erratum in:Cancer Res. 59:2020 (1999).
Bustami, R.T., et al., “Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide,”Pharm. Res. 17:1360-1366 (2000).
Dong, A., et al., “Infrared spectroscopic studies of lyophilization- and temperature-induced protein aggregation,”J Pharm Sci. 84:415-424 (1995).
Dong, A., et al., “Secondary structure of the pentraxin female protein in water determined by infrared spectroscopy: effects of calcium and phosphorylcholine,” Biochemistry 31:9364-9370 (1992).
Giegé, R., et al., “An introduction to the crystallogeneis of biological macromolecules”,Crystallization of Nucleic Acids and Proteins, a Practical ApproachOxford University Press, 2nded., 1-16 (1999).
Gilding, D.K., et al., “Biodegrabale polymers for use in surgery-polyglycolic/poly(actic acid) homo- and copolymers:1,”Polymer20:1459-1464 (1981).
Gombotz W.R., et al., “Biodegradable polymers for protein and peptide drug delivery,”Bioconjug. Chem. 6:332-351 (1995).
Heller, J., et al., “Theory and Practice of Controlled Drug Delivery from Biodegradable Polymers,”Controlled Release of Bioactive Materials Academic Press, 1-17 (1980).
Lehmann, K.O.R., et al., “Controlled Drug Release from Small Particles Encapsulated with Acrylic Resins,”Polymeric Delivery Systems. 111-119 (1979).
Morita, T., et al., “Formation and Isolation of spherical fine protein microparticles through lyophilization of protein-poly(ethylene glycol) aqueous mixture,”Pharm. Res. 17:1367-1373 (2000).
Pekarek, K.J., et al., “Double-walled polymer microspheres for controlled drug release,”Nature367:258-260 (1994).
Pietras, R.J., et al., “Monoclonal antibody to HER-2
eureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene,”Cancer Res. 59:1347-1355 (1999).
Ramadan, E.M., et al., “Effect of encapsulation of mefenamic acid with cationic Eudragit E on its bioavailability and gastric ulcerogenic activity in rabbits,”Journal of Microencapsulation4:125-132 (1987).
Ruth, L., et al., “alpha-L-iduronidase forms semi-crystalline spherulites with amyloid-like properties,”Acta. Crystallogr. D. Biol. Crystallogr. 56:524-528 (2000).
Kuznetsov, Yu G et al., “Chimeric Human-Simian Anti-CD4 Antibodies Form Crystalline High Symmetry Particles” Journal of Structural Biology vol. 131, pp. 108-115 (2000).
Thompson et al. “Purification of Eukaryotic RNA Polymerase II by Immunoaffinity Chromatography”, vol. 265, No. 12, pp. 7069-7077, Apr. 1990.
Adams, et al., (1999) “Generating improved single-chain Fv molecules for tumor targeting,” Journal of Immunological Methods, v. 231, pp. 249-260.
Bertolini, et al., (2000) “Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma,” Neoplasia, v. 96, pp. 282-287.
Blanco, et al., (1998) “Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants,” Eur. J. Pharm. Biopharm. v. 45, pp. 285-294.
Boehm, et al., (2000) “Crystal structure of the anti-(cacinoembryonic antiggen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts,” The Biochemical Journal, v. 346, pp. 519-528.
Braden, et al., (2000) “X-ray crystal structure of an anti-Buckminsterfullerene antibody Fab fragment: Biomolecular recognition of C.sub.60,” Proc. Natl. Acad. Sci. USA, v. 97, pp. 12193-12197.
Brange, et al., (1992) “Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations,”) Pharm. Res., v. 9, pp. 715-726.
Chayen (2004), “Turning protein cry

Affiliated with

Also associated with

Rating

Spherical protein particles and methods for making and using... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Spherical protein particles and methods for making and using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spherical protein particles and methods for making and using... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2738094